Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for H3K27M-mutant Diffuse Midline Glioma (DMG)
This study is testing a new way to fight a specific type of brain or spinal cord tumor called H3K27M-mutant diffuse midline glioma. Researchers are using a special treatment called CAR T-cell therapy, which trains your own immune cells to find and attack cancer cells.
This trial is open to children and adults between 2 and 60 years old who have a tumor with the H3K27M or H3K27I gene mutation. You must have finished recent radiation or chemotherapy treatments a few weeks before joining.
You will receive modified immune cells designed to target your tumor, along with some chemotherapy drugs that help your body prepare for the therapy. Doctors will carefully monitor your health to see if the treatment is safe and effective.
The study is currently recruiting new participants and is located at Stanford, California. It is a Phase 1 trial, which means it is in the early stages of testing safety.
- 1Uses your own cells to help fight the cancer.
- 2Requires a specific genetic mutation found in the tumor.
- 3Carefully monitored by a team of specialists to ensure safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.